SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
The Appalachian Mountains are a vast mountain range situated in eastern North America, extending roughly 2,050 miles (3,300 km) from central Alabama to Newfoundland along a generally southwest–northeast axis. Alongside the Appalachian Plateau province—with which they are not entirely synonymous—the mountains form a wider system comprising the region's backbone. The range's highest peak is 6,684-foot (2,037 m) Mount Mitchell in the Black Mountains subrange of North Carolina, which themselves are part of the larger Blue Ridge Mountains. Saint Pierre and Miquelon, an overseas collectivity of France, is part of the range, meaning it technically spans portions of three countries. It is geologically related to the Scottish Highlands, Atlas Mountains, Scandinavian Mountains, and Ouachitas, as these ranges all originally belonged to the sprawling Central Pangean Mountains before plate tectonics tore them apart. The geologic processes that led to the formation of the Appalachian Mountains started around 1.1 billion years ago with the creation of supercontinent Rodinia, and many Precambrian rocks and minerals created via this process remain visible today in the range's outcrops. The modern Appalachians and their relatives themselves were created by a series of three distinct orogenies beginning approximately 480 million years ago, making them one of the oldest surviving mountain ranges in the world.
lanthanum barium copper oxide (LB–CO), TC = −240 °C (35 K). yttrium barium copper oxide (YB–CO), TC = −215 °C (93 K). bismuth strontium calcium copper oxide (BiSC–CO), TC = −180 °C (95 K). thallium barium calcium copper oxide (TBC–CO), TC = −150 °C (125 K). mercury barium calcium copper oxide (HGBC–CO) 1993, with TC = −140 °C (133 K), currently the highest cuprate critical temperature. In 2018, the full three dimensional Fermi surface structure was derived from soft x-ray ARPES.
== Early life == Tracy Lauren Marrow, the son of Solomon and Alice Marrow, was born in Newark, New Jersey on February 16, 1958. Solomon's family was originally from Virginia and Philadelphia, and Alice's family was originally from Louisiana. Both of his parents were African American. Ice-T states that his father was a "dark-skinned brother" while his mother was a "fair-skinned" black woman who looked like Dorothy Dandridge or Lena Horne. For decades, Solomon worked as a conveyor belt mechanic at the Rapistan Conveyor Company. When Marrow was a child, his family moved to upscale Summit, New Jersey. The first time race played a major part in Marrow's life was at the age of seven, when he became aware of the racism leveled by his white friends towards black children. Marrow surmised that he escaped similar treatment because they thought that he was white due to his lighter skin. Relaying this incident to his mother, she told him, "Honey, people are stupid"; her advice and this incident taught Marrow to control the way the negativity of others affected him. His mother died of a heart attack when he was in third grade. Solomon raised Marrow as a single father for four years, with help from a housekeeper. Marrow's first experience with illicit activity occurred after a bicycle that his father bought him for Christmas was stolen. After Marrow told his father, Solomon shrugged, "Well, then, you ain't got no bike".
Sources: en.wikipedia.org
deoxycytidine Abbreviated in shorthand with dC. One of the four standard deoxyribonucleosides used in DNA molecules, consisting of a cytosine base with its N9 nitrogen bonded to the C1 carbon of a deoxyribose sugar. Cytosine bonded to ribose forms an alternate compound known simply as cytidine, which is used in RNA.
Other theories of inheritance preceded Mendel's work. A popular theory during the 19th century, and implied by Charles Darwin's 1859 On the Origin of Species, was blending inheritance: the idea that individuals inherit a smooth blend of traits from their parents. Mendel's work provided examples where traits were definitely not blended after hybridization, showing that traits are produced by combinations of distinct genes rather than a continuous blend. Blending of traits in the progeny is now explained by the action of multiple genes with quantitative effects. Another theory that had some support at that time was the inheritance of acquired characteristics: the belief that individuals inherit traits strengthened by their parents. This theory (commonly associated with Jean-Baptiste Lamarck) is now known to be wrong—the experiences of individuals do not affect the genes they pass to their children. Other theories included Darwin's pangenesis (which had both acquired and inherited aspects) and Francis Galton's reformulation of pangenesis as both particulate and inherited.
=== Churches === Le Havre Cathedral: the first stone of the building was laid in 1536. It is the seat of the Bishop of Le Havre. Church of Saint Joseph, one of the most recognized symbols of the city. The belltower is one of the tallest in France, rising to a height of 107 metres. It was designed by Auguste Perret. Church of Saint Michel Church of Saint Vincent Church of Saint François Church of St. Anne Church of Saint Marie Chapel of Saint Michel d'Ingouville (15th century) Graville Abbey, a monastery dedicated to Sainte Honorine, set in grounds on the northern bank of the Seine River. Presbyterian Reform Church (Église Réformée), 47 rue Anatole France, built in 1857, bombed in 1941, the roof and ceiling were rebuilt in 1953 by two architects from the famous Auguste Perret office: Jacques Lamy and Gérard Dupasquier, The only building in town offering both ancient and the new Perret school of architecture in the same building. Holy Office each Sunday morning at 10.30.
=== S phase (interphase) extract === When CaCl₂ is added to an M-phase Xenopus egg extract at a concentration sufficient to override residual EGTA (typically several hundred micromolar), it triggers rapid inactivation of maturation promoting factor (MPF). This occurs through cyclin B degradation by the proteasome and induces cell cycle progression from metaphase to anaphase, and eventually into S phase. The resulting extract is referred to as an S-phase extract or interphase extract. Upon the addition of sperm chromatin to an S-phase extract, nuclear assembly is initiated: membrane vesicles accumulate around decondensed chromatin, fuse to form a nuclear envelope, and produce fully functional nuclei. Active nuclear transport occurs across the nuclear envelope, and DNA replication is initiated within the reconstituted nuclei. Because these extracts contain abundant mRNA and ribosomes, protein translation also takes place. Thus, this cell-free system can faithfully recapitulate many cellular events characteristic of proliferating cells. A notable exception is transcription, which does not occur in this system. This reflects the natural state of the Xenopus egg and early embryo, where transcription is largely repressed from the meiotic stages through to the blastula stage after fertilization.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.